GlobeImmune

GlobeImmune Inc. is a U.S.-based biopharmaceutical company focused on developing products for the treatment of cancer and infectious diseases based on its proprietary Tarmogen platform. It has developed several Tarmogen candidates for infectious diseases and various cancer indications. The company’s pipeline products include GS-4774, GI-19000, GI-2010, and GI-18000, which target HBV and HIV antigens, TB antigens, Delta virus antigens, and tumor product candidates such as GI-6207, GI-6301, and GI4000, targeting Carcinoembryonic antigen, Brachyury, and Mutated Ras.